RT Journal Article
SR Electronic
T1 Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.06.20120386
DO 10.1101/2020.07.06.20120386
A1 Dublin, Sascha
A1 Walker, Rod
A1 Floyd, James S.
A1 Shortreed, Susan M.
A1 Fuller, Sharon
A1 Albertson-Junkans, Ladia
A1 Harrington, Laura B.
A1 Greenwood-Hickman, Mikael Anne
A1 Green, Beverly B.
A1 Psaty, Bruce M.
YR 2020
UL http://medrxiv.org/content/early/2020/07/07/2020.07.06.20120386.abstract
AB There are plausible mechanisms by which angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may increase the risk of COVID-19 infection or affect disease severity. To examine the association between these medications and COVID-19 infection or hospitalization, we conducted a retrospective cohort study within a US integrated healthcare system. Among people aged ≥18 years enrolled in the health plan for at least 4 months as of 2/29/2020, current ACEI and ARB use was identified from pharmacy data, and the estimated daily dose was calculated and standardized across medications. COVID-19 infections were identified through 6/14/2020 from laboratory and hospitalization data. We used logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence intervals. Among 322,044 individuals, 720 developed COVID-19 infection. Among people using ACEI/ARBs, 183/56,105 developed COVID-19 (3.3 per 1000 individuals) compared with 537/265,939 without ACEI/ARB use (2.0 per 1000), yielding an adjusted OR of 0.94 (95% CI 0.75-1.16). For use of < 1 defined daily dose vs. nonuse, the adjusted OR for infection was 0.89 (95% CI 0.62-1.26); for 1 to < 2 defined daily doses, 0.97 (95% CI 0.71-1.31); and for ≥2 defined daily doses, 0.94 (95% CI 0.72-1.23). The OR was similar for ACEIs and ARBs and in subgroups by age and sex. 29% of people with COVID-19 infection were hospitalized; the adjusted OR for hospitalization in relation to ACEI/ARB use was 0.92 (95% CI 0.54-1.57), and there was no association with dose. These findings support current recommendations that individuals on these medications continue their use.Competing Interest StatementDr. Dublin has received grant funding from Jazz Pharmaceuticals for unrelated work. She is a co-investigator on a grant that is pending from GSK on an unrelated topic. Dr. Shortreed has been a co-Investigator on Kaiser Permanente Washington Health Research Institute (KPWHRI) projects funded by Syneos Health, who is representing a consortium of pharmaceutical companies carrying out FDA-mandated studies regarding the safety of extended-release opioids. Dr. Floyd has consulted for Shionogi Inc. Dr. Psaty serves on the Steering Committee of the Yale Open Data Access Committee funded by Johnson & Johnson. From September 2019 to December 2020, Dr. Green is serving as a co-Investigator on a contract awarded to the Kaiser Foundation Health Plan of Washington from Amgen to evaluate the accuracy of using electronic health record data to identify individuals with reduced ejection fraction heart failure. Other authors have nothing to disclose.Funding StatementThis work was supported by Kaiser Permanente Washington Health Research Institute internal funds. Dr. Floyd was supported by National Heart, Lung, and Blood Institute (NHLBI) grant R01HL142599. Dr. Harrington was supported by NHLBI grant K01HL139997.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kaiser Permanente Washington Institutional Review Board provided approval under file number IRBNet 1586996.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon request, the authors will freely share the study protocol and statistical code. After the primary paper has been published, study data could be shared with approved individuals for specific research purposes through written agreements with the authors and with Kaiser Permanente Washington Health Research Institute.